Survival outcomes in multiple myeloma have significantly improved thanks to decades of treatment advances. With more than half of the 11 innovative therapies approved for its treatment in the past two decades, Johnson & Johnson has helped transform patients’ lives with numerous approved innovative treatments. We aim to develop curative therapies, with urgency, and shifting the treatment paradigm from “treat-to-progression” to “treat-to-cure”.
Multiple myeloma is the second most common blood cancer, with nearly 176,000 new cases diagnosed worldwide every year.
Our comprehensive portfolio explores treatments that employ a range of mechanisms of action and hit different cellular targets based on a patient’s unique disease characteristics. Our goal is to maximize available options by developing complementary approaches to treating multiple myeloma using bispecific T-cell engagers, CAR-T therapies, and the current standard of care therapy. We are deepening our commitment to lead the advancement of science and innovation across disease states and lines of treatment to help unlock transformational outcomes for patients.
Plasma cell malignancies: multiple myeloma by the numbers
- Second most common blood cancer
- Nearly 176,000 new cases diagnosed worldwide every year
